Matthew C. Lee, MD, MPH
Disclosures: Nothing to disclose - 05/01/2024

 

 

1

Matthew Lee

mattlee52391@gmail.com

1-(347) 837-5787    

Education

_________________________________________________________________________________________________

 

Combined BA/MD program

Brooklyn College                                                                                                                                                                        Jun 2013

 

Medical Degree (MD) and Master's in Public Health (MPH)

State University of New York (SUNY) Downstate Medical School                                                                                                Jun 2017

●        Master’s in Public Health: concentration Epidemiology

_________________________________________________________________________________________________

 

Postgraduate training

_________________________________________________________________________________________________

 

Internal Medicine Internship and Residency

Donald and Barbara Zucker School of Medicine at Hofstra

Northwell North Shore University and Long Island Jewish Medical Center                                                                  Jul 2017 – Jun 2020

 

Hematology-Oncology Fellowship

Albert Einstein College of Medicine/Montefiore Medical Center                                                                              Jul 2020 – June 2023

Montefiore-Einstein Comprehensive Cancer Center

  • Concentrations
    • Thoracic Oncology: research focused on small-cell lung cancer, the optimal use and duration of immunotherapy, next-generation immunotherapies, and cellular therapies in phase I, real-world data studies and public health/quality improvement issues in lung cancer including socioeconomic and racial disparities in immunotherapy and TKIs use

_________________________________________________________________________________________________

 

Professional employment and Hospital Appointments

_________________________________________________________________________________________________

 

Assistant Professor

Montefiore Einstein Comprehensive Cancer Center (MECCC)                                                                         September 2023-current

Thoracic Oncology

Phase One Thoracic Oncology liaison

 

Director of Inpatient Oncology                                                                                                                                September 2023-current

Weiler-Einstein Hospital

Montefiore Medical Center-Einstein Division Council leadership member                                                                                   

_________________________________________________________________________________________________

ABIM Board certification:

 

Medical Oncology                                                                                                                                                        November 2023                           

Hematology                                                                                                                                                                       November 2022

 

Internal Medicine                                                                                                                                                                       August 2020

__________________________________________________________________________________________

 

Research and Publications

_________________________________________________________________________________________________

 

Ongoing Clinical Trials and Research Projects

  • ECOG EA5233: Phase III trial of the Evaluation of the Optimal duration of immunotherapy in advanced NSCLC patients: The (EONS) study

Role: National Principal Investigator

Co-PI: Balazs Halmos

Sub-PIs and co-investigators: Julie Brahmer, Hossein Borghaei, Josephine Feliciano, Valsamo Anagnostou

    • Status: approval from executive ECOG committee, pending further revisions for ECOG Steering committee review and CTEP submission
    • A proposed multicenter randomized Phase III trial on advanced/metastatic NSCLC patients that have completed 18 months to 2 years of pembrolizumab with or without chemotherapy randomized to either an additional 2 years of pembrolizumab or active surveillance with radiographic imaging and an exploratory correlative with ctDNA monitoring. Primary proposed measure would be PFS and secondary measures of OS.   

 

  • A Phase III, Randomized, Double-blind,Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306) (Amgen) NCT06117774

Role: Site Principal Investigator

    • Status: site selected, pending accruals and trial activation

 

  • A Phase III, Multicenter, Randomized, Open-Label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician’s Choice (TPC) in Subjects with Relapsed Small Cell Lung Cancer (SCLC) (Daiichi-Sankyo) (NCT05280470)

Role: Site Principal Investigator

    • Status: site selected, pending accruals and trial activation

 

  • A Phase III Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NCT04928846)

Role: Site Principal Investigator

    • Status: site selected, pending accruals and trial activation

 

  • A Phase IV Study of Apricity C.A.R.E. Program for Cancer Adverse Events Rapid Evaluation to Improve Treatment Outcomes of Ethnic/Racial Minority Non-small Cell Lung Cancer (NSCLC) Patients Receiving Immune Checkpoint Inhibitors (ICI) (NCT NCT05812274)

Role: Sub-Principal Investigator and MECCC site champion

PI: Brian Henick (Columbia University)

    • Status: ongoing study with Apricity CARE and Stand Up 2 Cancer grant with Columbia, Cornell, NYU and Mt Sinai
    • A multi-center (Columbia Univeristy, NYU, Mt Sinai and Montefiore) phase IV clinical trial evaluating a 24/7 symptom monitoring program called Apricity CARE works. It provides a smart phone app and allows for patients to report treatment side effects notifying a nurse to evaluate the symptoms.  This trial is designed a to 1) assess factors related to suboptimal and optimal use of the ApricityCARE program (entailing both an app and monitoring service) and 2) determine the impact of the program on ICI toxicity for NSCLC patients receiving ICIs in a highly diverse community. The study entails a 50-patient run-in phase with two focus group discussions, stratified on a Likert-type scale based on the frequency of utilization, to determine factors impacting usability of the ApricityCare program. This data will inform optimal implementation of ApricityCare for the randomized phase of the study, where 230 patients will be assigned 1:1 to use of ApricityCare versus standard of care.

 

  • Evaluation of the Genomic and Immune Profiles of patients with Lung Adenosquamous Carcinoma (LUAS) and Association of Response to Treatment. Matthew Lee, Tolulope Adeyelu, Shuai Wang, Andrew Elliott, Ari Vanderwalde, Liza Villaruz, Hina Khan, Benjamin Herberg, So Yeon Kim, Patrick Ma, Stephen Liu, Balazs Halmos, Haiying Cheng

Role: Principal Investigator

    • Status: Submitted to ASCO Abstract 2024 and IASLC WCLC 2024, pending further evaluation
    • Examination of the mutational landscape and clinical outcomes of adenosquamous patients in the database of the next-generation sequencing platform, Caris. Preliminary data revealed that patients with LUAS exhibit at least 29% actionable alterations with an enrichment in METex14. Clinical outcomes have shown that LUAS has improved OS compared to lung squamous cell cancer but not to lung adenocarcinoma. No association seen with PD-L1 status.

 

 

 

  • Evaluation of the genomic landscape and association of TRAEs in advanced NSCLC long-term immunotherapy responders

Role: Principal Investigator

    • Status: Ongoing retrospective data collection on MECCC lung cancer data registry evaluating in-house sequencing and commercial next-generation sequencing (FoundationOne, Caris, Guardant360) data on advanced NSCLC patients who have responded to immunotherapy regimens for at least 18 months or more. Limited studies have examined the genomic profile of these long-term responders and also whether race/ethnicity are associated with the mutational profiles of these patients. Further, evaluation of their TRAEs will also be examined along with clinical outcomes.

 

  • Treatment adherence, clinical outcomes and pharmacogenetics among ethnic-minority patients with EGFR-mutated NSCLC treated with Osimertinib. Lee M, Miao E, Zhang C et al.  Journal of Clinical Oncology 2023; 41 (16_suppl): e18536-e18536. https://doi.org/10.1200/JCO.2023.41.16_suppl.e18536

Role: Sub-Principal Investigator

PI: Haiying Cheng

    • Status: Presented at WCLC 2023 Poster session (Early Career Education Award), ongoing collection of prospective correlative pharmacogenetic and Osimertinib pharmacodynamics and retrospective data collection
    • A combined retrospective and prospective study evaluating the use of Osimertinib in African Americans. Previous studies have shown African Americans may possess different clinical characteristics and responses to targeted therapies due to weight differences and CYP3A4/5 metabolism. Furthermore, treatment adherence and healthcare disparities with socioeconomic determinants such as cost and insurance can also play a role in Osimertinib treatment duration, and study was aimed on developing strategies to optimize the usage of Osimertinib in advanced EGFR-mutated NSCLC patients. The co-primary objectives are to determine PFS from the start of Osimertinib and barriers to treatment adherence and predictors of treatment discontinuation retrospectively at the multi-hospital site Montefiore health system. Secondary objectives of identifying predictors of OS and ORR and evaluating steady-state concentrations of Osimertinib in patients receiving treatment and evaluation of pharmacogenomics prospectively as correlative studies.
    • Retrospective results currently reported have shown that although there was high adherence rates of 83-87% based on MPR and PDC with no differences among the different racial/ethnic group, there  was a higher mortality risk in Non-Hispanic Blacks compared to Non-Hispanic Whites in a multivariate analysis adjusting for race/ethnicity, age, smoking, income, stage, histology and adherence.

 

  • Comparing clinical outcomes and safety between first-line treatments for advanced large-cell neuroendocrine tumors of the lung

Role: Principal Investigator (site) and Overall PI: Annie Chiang (Yale University)

    • Status: Ongoing data collection and analysis
    • Multi-center retrospective study involving 30+ cancer center in the US and abroad. Aim is to compare the clinical outcomes and safety profile of three approaches to advanced/metastatic large-cell neuroendocrine tumors of the lung: dual immunotherapy vs combined immunotherapy/chemotherapy vs chemotherapy only. The main hypothesis that patients with large-cell neuroendocrine tumors of the lung derive 1) at least equivalent clinical outcomes in patients treated with immune checkpoint inhibitors vs combined chemoimmunotherapy 2) achieve superior clinical outcomes compared to patients treated with only chemotherapy or without disease-directed therapy (i.e. on observation). 3) We hypothesize that the immunotherapy and chemotherapy agents are safe to administer in this patient population, both in isolation and combine

 

  • ASCO Quality Improvement (QI) Training Program 2024
    • Role: Site Principal Investigator
    • Status: ongoing
    • A 6-month program through ASCO on quality improvement strategies and coaching. The ongoing QI initiative involves evaluating an increase of central line associated blood stream infections and to improve quality of cancer care delivery in the inpatient setting with a multidisciplinary team of fellows and nurses and staff on strategies and tools to decrease infection rates

 

  • IASLC Academy 2024 
    • Role: selected participant
    • Proposed research project and pending presentation at the 2024 Academy Workshop on 9/6/24, planned online activities and mentorship, patient case report for the 2024 Amazing Case Race simulation activity

 

Ongoing Phase I Thoracic trial involvement

  • A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody (NCT05662397)
    • Phase 1/2, HST-1011 (oral allosteric CBL-B, regulator of effector cell immunity) as monotherapy or in combination with Cemiplimab for relapsed/refractory advanced tumors from prior anti-PD(L)1 therapies, HotSpot Therapeutics
  • Study of DF1001 in Patients With Advanced Solid Tumors (NCT04143711)
    • Phase 1/2, DF-1001 (Tri-specific antibody that engages NK cells and T-cell activation), targetting HER2 and coengaging CD16 and NKG2D, basket trial with advanced tumors with high HER2 levels, combination DF1001+Nivolumab and DF1001 + Nab-paclitaxel arms, Dragonfly Therapeutics. Expansion cohorts to include monotherapy and Sacituzumab govitecan-hziy combination with DF1001, Dragonfly Therapeutics
  • A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors (NCT05225584)
    • KT-333, STAT3 protein degrader with preclinical durable tumor regression, now being tested in a phase I and in specifically NSCLC with STK11/LB1 mutations, Kymera Therapeutics
  • A Study of DF6002 Alone and in Combination With Nivolumab (NCT04423029)
    • Phase 1, DF-6002, Monovalent and Fc-protratcted IL-12 cytokine immunotherapy evaluated as monotherapy or in combination with nivolumab with advanced or metastatic solid tumors, Dragonfly Therapeutics
  • A Study to Investigate LYL797-101 in Adults With Solid Tumors (NCT05274451)
    • LYL-797, ROR1-specific CAR-T, evaluating in replased/refractory NSCLC and TNBC, Lyell Immunopharma Inc
  • P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors (NCT05239143)
    • MUC1-C targeting allogenic CAR-T, all epithelial derived solid tumors, Poseida Therapeutics
  • Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (NCT03907852)
    • TC-210, Mesothelin-Targeting TruC T Cell Therapy, TCR2 therapeutics and Bristol-Myers Squibb, closed for accrual for now due to TRAEs, TCR2 Therapeutics and Bristol-Myers Squibb
  • An Open-Label, Multicenter, Phase I study of AN4005 in Patients with Advanced Tumors (NCT04999384)
    • AN4005 is an oral PD-L1 inhibitor, single arm and monotherapy and open for all advanced solid tumors
  • A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2
    • NPX267-001, antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2), including cancers expressing HHLA2 and EGFR NSCLC, NextPoint Therapeutics Inc

 

Pending Publications and Manuscripts

  • A phase II trial of Abiraterone with Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer (Local IRB protocol# 2017-8506)

Role: Sub-Investigator

PI: Benjamin Gartrell

    • Status: completed enrollment and pending publication
    • Single institution, single arm, phase II trial with metastatic prostate cancer will be treated with abiraterone acetate and prednisone without a GnRH analogue and primary objective to assess the proportion of patients during treatment period have serum testosterone rise to non-castrate levels (>50 ng/dL). Secondary objectives include luteinizing hormone (LH), during treatment period, PSA response rate, PFS, median OS and monitor safety profile. Pending biostatistics review and publication

 

Published Peer-Reviewed Publications

●        Similar Efficacy observed for Frontline Immunotherapy in Ethnic-Minority patients with Metastatic NSCLC.

Lee M, Liu J, Miao E, Wang S, Zhang F, Wei J, Chung J, Xue X, Halmos B, Hosgood D, Cheng H. J Natl Compr Canc Netw. 2023 Dec;21(12):1269-1280.e5. doi: 10.6004/jnccn.2023.7064. PMID: 38081123.

o         Retrospective analysis of NSCLC patients from 1/1/2013 to 12/13/18 that received immunotherapy and evaluated primarily OS and secondary objectives of PFS, duration of time on immunotherapy and disease control rate (DCR). Results showed similar OS, PFS and treatment duration among the different race and ethnicity groups and the report states about the different socioeconomic factors such as income, insurance, BMI may also affect clinical outcomes of PFS.

●         Book Chapter: Physicians’ Cancer Chemotherapy Drug Manual 2023, Edward Chu and Vincent Devita. Jones & Bartlett Learning, 23rd edition

o         Chapter 4 “Common Chemotherapy Regimens in Clinical Practice” in Lung Cancer regimens. Participated as a contributing author and assisting Dr Edward Chu in compiling a focused updated list and analysis of new emerging treatments in lung cancer and other malignancies for next year’s edition of Physicians’ Cancer Chemotherapy Drug Manual 2023.

●        Book Chapter: “Targeting Oncogenic Driver Mutations in Lung Cancer” (invited authorship) Lee, M., Abu Rous, F., Borczuk, A., Liu, S., Gadgeel, S., & Halmos, B. (2023). Targeting Oncogenic Driver Mutations in Lung Cancer (Elements in Molecular Oncology). Cambridge: Cambridge University Press. doi:10.1017/9781009336123

    • A comprehensive review chapter on clinically relevant oncogenic driver mutations other than EGFR. Examples include ALK, ROS1, BRAF, RET, MET, NTRK, HER2 and the different current and novel treatment options. Additionally, diagnostic issues and testing were also discussed and possible future diagnostic and treatment strategies.
  • Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial. Thakkar A, Pradhan K, Duva B, Carreno JM, Sahu S, Thiruthuvanathan V, Campbell S, Gallego S, Bhagat TD, Rivera J, Choudhary G, Olea R, Sabalza M, Shapiro LC, Lee M, Quinn R, Mantzaris I, Chu E, Will B, Pirofski LA, Krammer F, Verma A, Halmos B. Elife. 2023 Mar 28;12:e83694. doi: 10.7554/eLife.83694. PMID: 36975207; PMCID: PMC10129324.
    • A study on evaluating the immune response to a 3rd COVID vaccine and the effectiveness of a 4th dose. Our results showed there was a seroconversion in 57% of patients that were initially seronegative after primary vaccination and demonstrated durability at 6 months followup. A 4th dose was given to hematologic malignancy patients who were unable to mount an adequate immune response after the 3rd dose and this led to a 67% immune-boost. These results indicate that additional vaccination is able to continue to illicit a durable response and can convert even those who were previously seronegative

●        Efficacy and longevity of immune response to 3rd COVID-19 vaccine and effectiveness of a 4th dose in severely immunocompromised patients with cancer

Thakkar A, Pradhan K, Duva B, Carreno B, Sahu S, Thiruthuvanathan V, Campbell S, Gallego S, Bhagat T,  Rivera J, Choudhary G, Olea R, Sabalza M, Shapiro L, Lee M,  Quinn R, Mantzaris I, Chu E, Will B, Pirofski L,  Krammer F, Verma A, and Halmos B. medRxiv; 2022 July. DOI: 10.1101/2022.07.05.22277281.

●        Assessment of COVID-19 Vaccine Hesitancy in an Ethnic Minority Oncology Patient Population. Lee M, Miao E, Viswanathan S, Rapkin B, Halmos B, Goel S. Journal of Clinical Oncology. 2022 June 2; 40, suppl 16 e18570. doi: 10.1200/JCO.2022.40.16_suppl.e18570

o         Cross-sectional survey between 2/1/2021-6/30/2021on adult (>18 years old) cancer patients treated at a single institution and results showed that those with a higher knowledge of COVID-19 and greater than high school education was more likely to be vaccinated with blacks being two times as more likely to be vaccinated. This information can help tailor future vaccination campaigns and pending further long-term followup on vaccination status.

●        Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave. Lee M, Quinn R, Pradhan K, Fedorov K, Levitz D, Fromowitz A, Thakar A, Shapiro L, Kabarriti R, Ruiz R, Andrews E, Thota R, Chu E, Kalnicki S, Goldstein Y, Loeb D, Racine A, Halmos B, Mehta V, Verma A. Cancer Cell. 2022 Feb 22;S1535-6108(22)00064-2. doi: 10.1016/j.ccell.2022.02.012.

o         Retrospective analysis of the SARS-CoV-2 Omicron variant impact on patients with malignancies. Results showed that the case fatality rate (CFR) was 4.9% among those with cancer cohort which although is lower than the previous variants of SARS-CoV-2, when compared to a control group with no malignancies with a CFR of 1.02%, cancer patients still had a significantly higher mortality (p=0.0022). Furthermore, those who were fully vaccinated had a statistically lower mortality in both the control and cancer cohorts (p=6.63 E-05). Of those cancer patients who had passed away from COVID-related deaths, none had booster vaccines and may highlight the importance of booster vaccination in this high-risk group and an area of improvement to focus on increasing the uptake of booster vaccinations.

●        First case of DRESS (drug reaction with eosinophilia and systemic symptoms) associated with voxelotor. Lee M, Stringer T, Jacob J, Friedman E, Minniti C, Billett H, Curtis S. Am J Hematol. 2021 Nov 1;96(11):E436-E439. doi: 10.1002/ajh.26342. Epub 2021 Sep 14.

o         Literature review and first case report of Voxelotor leading to DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome and the different management strategies to resolve it.

●        Large Cell Neuroendocrine Carcinoma Transformation as a Mechanism of Acquired Resistance to Osimertinib in Non-small Cell Lung Cancer: Case Report and Literature Review. Lee M, Patel D, Jofre S, Fidvi S, Suhrland M, Cohen P, Cheng H. Clin Lung Cancer. 2021 Aug 10, S1525-7304(21)00206-0. doi: 10.1016/j.cllc.2021.08.002

o         Case report and Literature Review on Large Cell Neuroendocrine Transformation as a mechanism for acquired resistance to Osimertinib in NSCLC patients. The article highlights the importance of repeat diagnostic testing and biopsies and the possible utility of ctDNA in progression of disease. 

●        MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies. Lee M, Jain P, Wang F, Ma Patrick, Borczuk A, Halmos B. Expert Opin Ther Targets. 2021 Apr;25(4):249-268. doi: 10.1080/14728222.2021.1925648. Epub 2021 Jun 13

o         A comprehensive literature review on MET alterations in NSCLC and the various types of mutations that have oncogenic potential. It also goes into the various diagnostic techniques and treatments available currently and the new novel treatments that are being developed to optimize management.

●        Multiple Myeloma in a Young Female Presenting with Neurological Symptoms. Lee M, Zhang X, Nguyen V, Hartley-Brown M. Case Rep Hematol. 2020;2020:1375174. Published 2020 Feb 13. doi:10.1155/2020/1375174

o         A case report and literature review on a patient found to have multiple extramedullary plasmacytomas and multiple myeloma initially presenting with ataxia and diplopia. This case and literature review shows an example of how a young patient may present, how it can be managed and the prognosis of these patients and the usage of Daratumumab regimens in this setting.

●        An Atypical presentation of Lichen Planus like reaction from Pembrolizumab. Lee M, Seetharamu S. Case Rep Dermatol Med. 2019;2019:4065437. Published 2019 Jul 7. doi:10.1155/2019/4065437

o         A case report and literature review on a patient that presented with pustular bullous lesions on the feet and hands, that was found to be found to lichen planus and treated with topical and oral steroids and cessation of Pembrolizumab. The case and literature review highlights the cutaneous side effects of immunotherapy and ways of management

●        A Rare Presentation of Zosteriform Pattern of Cutaneous Metastases from Lung Cancer: A Case Report and Literature Review on Cutaneous Metastases in Non-Small Cell Lung Cancer. Lee M, Sheth S, Ahmad S, Chang Q, Seetharamu N. J Cancer Sci Ther (2019) 11: 025-027. doi: 10.4172/1948-5956.1000578

o         A case report and literature review on a patient that initially presented with a large cutaneous chest mass and Zosteriform rash that was found to be a metastasis from a primary lung adenocarcinoma.  This case highlights the importance of recognizing cutaneous masses and metastasizes in patients with risk factors for lung cancer as potentially the first signs of lung cancer. This patient was asymptomatic except for his skin rash, and mass and it should be considered on a differential diagnosis when evaluating patients with cutaneous masses and rashes.

 

Conference Abstracts

  • Treatment adherence and clinical outcomes of Osimertinib (Osi) Among Ethnic-Minority Patients (pts) with EGFR-mutated NSCLC. WCLC 2023 (Singapore, in-person presentation and Early Career Award) and ASCO 2023 J Clin Oncol 41, 2023 (suppl 16) https://doi.org/10.1200/JCO.2023.41.16_suppl.e18536

o         Analysis of a retrospective database on EGFR mutated NSCLC patients at MECCC treated with osimertinib focusing on primary endpoint of OS and secondary endpoint of PFS and treatment duration. Treatment adherence did not differ among the different racial ethnic groups using adherence methods of medication possession ratio (MPR) and proportion of days covered (PDC). Compared to non-Hispanics, Hispanics had similar OS, PFS and treatment duration. However, compared with Non-Blacks, Blacks had inferior PFS (p=0.021) and borderline significance of worse OS (p=0.052) and shorter duration of Osi (p=0.068). Further studies are ongoing to examine the reasonings for this a nd a prospective collection of serum samples for pharmacogenetics is underway.

●         Clinical Effectiveness of First Line Immunotherapy in Small Cell Lung Cancer at World Conference on Lung Cancer (WCLC) (Singapore) 9/9-9/12/23 E-poster

o         Retrospective evaluation of extensive SCLC patients in an ethnically diverse patient population that received immunotherapy. OS, PFS and treatment duration were similar in all the different races (Hispanic, Non-Hispanic black and Non-Hispanic White) patients. However, there were statistically significantly higher income in Non-Hispanic Whites compared to Hispanics and Non-Hispanic Blacks along with insurance coverage differences.

●         Similar Efficacy of Frontline Immunotherapy in Ethnic-Minority patients with Metastatic NSCLC as a poster finalist presentation at Texas Lung Conference (TLC) (Austin, Texas) 3/30-4/1/23 and WCLC 2023 (Singapore) E-poster

o         Examination of race/ethnicity and other demographic, socioeconomic and clinical factors of patients with metastatic NSCLC treated with first-line immunotherapy in our cancer center that serves a diverse patient population. Our study demonstrates that among the different races and ethnicities, they derive similar OS benefits of immunotherapy. However, factors such as ECOG status impact OS and BMI, insurance and PD-L1 significantly impact PFS and TTD

●       Mechanisms of Regorafenib Response and Resistance in Metastatic Colorectal Cancer as a poster presentation to ASCO Gastrointestinal Cancers Symposium (San Francisco, California) 1/19-1/21/2023 with ongoing correlative studies with pathology samples. Hsieh R, Lee M, Johnson D,  Zhang C, Moon J, Hsu D, Villaorduna A, Kuang C. J Clin Oncol 41, 2023 (suppl 4; abstr 135) 10.1200/JCO.2023.41.3_suppl.135

o         Evaluation of the potential resistance mechanisms of regorafenib including evaluating IHC expression of anti-apoptosis proteins (FBW7, MCL-1, BCL-2, BCL-W, BCL-XL) and molecular markers (KRAS, BRAF, TP53 etc). Another objective is to determine if lower immunosuppressive cells (Tregs, TH17, MDSCs) in the tumor microenvironment are correlated with poorer response to regorafenib. Lastly, another objective is to evaluate clinical outcomes retrospectively in a multicenter study to determine if race/ethnicity or mutations such as KRAS or BRAF are associated with the primary clinical outcome of survival and secondary outcomes of response rates, PFS and treatment duration.

●        Evaluation of CNS Involvement in Secondary AML: Incidence and Impact on Outcome

Lee M, Wei J, Narvel H, Vikash S, Kamel J, Lombardo A, Khatun F, Mustafa J, Joseph F, Naik A, Gillick K, Elkind R,Shi Y, Wang Y, Gritsman K, Steidl U, Goldfinger M, Kornblum N, Shastri A, Mantzaris I, Bachier L, Shah N, Konopleva M, Cooper D, Braunschweig I, Verma A, Goel S, Sica A Blood (2022) 140 (Supplement 1): 11653–11655. https://doi.org/10.1182/blood-2022-158112

    • CNS metastasis is rare in AML and the study aimed to investigate retrospectively the prevalence of CNS metastasis in secondary acute myeloid leukemia patients and characterize the risk factors leading to this poor prognosis and evaluate potential interventions to prevent it in Montefiore’s health system. Results currently show that with lower OS in those with secondary AML with CNS metastases compared to de-novo AML patients but not statistically significant (p=0.290). However, those with secondary AML with CNS metastases fared statistically worse than those without CNS metastases (p=0.044).  Further data collection on the impact of IT chemotherapy and RT has on OS and a comparison of all AML patients to this unique cohort.

●        Impact of clinical and pathological variables on stage I non-small cell lung cancer outcomes. Lee M, Stefanov D, Angert M, Cohn E, Kohn N, Esposito M, Seetharamu N. Journal of Clinical Oncology. 2020 May;25 38, no.15_suppl. doi: 10.1200/JCO.2020.38.15_suppl.e21071

o         A retrospective cohort of 351 stage I cases from 2015-2019 examining features including VPI (visceral pleural invasion), LVI (lymphovascular invasion), micropapillary pattern (MIP), spread through airspace (STAS) and neuroendocrine differentiation (NE) and whether any of them acted as prognostic factors, if there are any differences in how these patients responded to chemotherapy, targeted/immunotherapy, or surgeries. By analyzing if there are any differences in patients with these features and in patients without these features, it can better help individualize management plans for patients in determining whether they need medical or surgical interventions. Univariate models indicated significantly higher recurrence risk with NE, LVI, COPD, age and Charleston score and chemotherapy usage.

●        Is there a benefit of adding surveillance imaging to frequent history and physical exams in patients treated definitively for head and neck squamous cell carcinoma? Chi J, Sugarman R, Lee M, Kamdar D, Frank D, Pereira L, Gabalski E, Gonclaves P, Parashar B, Teckie S, Ghaly M, Seetharamu N. Journal of Clinical Oncology. 2019 May;26 37, no.15_suppl (May20, 2019) 6074-6074. doi: 10.1200/JCO.2019.37.15_suppl.6074

o         Role of surveillance imaging after initial 12-week post treatment PET/CT has no established guidelines, this project was a retrospective cohort study in examining with those who had a biopsy by surveillance imaging (PET, MRI, CT), those symptoms triggered imaging and a third group in a biopsy from a positive physical exam and calculated positive predictive value (PPV) of biopsy in each group. Positive symptom triggered imaging had the highest PPV, then physical exam and lastly surveillance imaging. Surveillance imaging found 45.6% of recurrence in asymptomatic patients and research still needed on optimal frequency and type.

●        A retrospective review on extended carboplatin infusion and incidence of hypersensitivity reaction in gynecologic malignancies in a single institution. Park J, Lee M, Kockenmeister E, John V. Journal of Clinical Oncology. 2019 May;26 37, no.15_suppl doi: 10.1200/JCO.2019.37.15_suppl.e17102

o         Carboplatin used for gynecologic malignancies are at risk for hypersensitivity reactions (HSR) and this project was a retrospective cohort study of comparing retreatment with extended infused carboplatin of 3 hours versus standard 1 hour and the rates of HSRs. It was found that there was more HSRs in 1 hour treated patients compared to 3-hour retreatment patients and for further studies on ways to prevent HSRs.

 

Presentations and Journal Clubs

______________________________________________________________________________________________

 

●         ECOG EA5233 EONS trial presentations: Evaluation of the Optimal duration of immunotherapy in advanced NSCLC patients: The (EONS) study

o         Monthly ECOG-ACRIN presentation on 3/23/22 virtually, initial presentation and proposal

o         Spring ECOG-ACRIN presentation on 5/5/22 in-person Chicago, revised protocol presentation

o         Fall ECOG-ACRIN presentation on 10/27/22 in-person Washington DC, revised protocol presentation

o         Spring ECOG-ACRIN presentation on 5/5/23 in-person Chicago, revised protocol presentation 

o         Fall ECOG-ACRIN presentation on 10/26/23 in-person Washington DC, revised protocol presentation

 

●        CME Updates in Lung Cancer Management on 11/3/23 (White Plains, New York): Small Cell Lung Cancer-New horizons (Oncolive)

o         Updates on new management and treatment options for SCLC patients from ASCO, WCLC and ESMO 2023

 

●        Post WCLC/ESMO Clinical Congress Consultants at Chemotherapy Foundation Society from Targeted Oncology and MJH on 11/10/22 and 11/11/22 (New York City, New York)

o         Examination of multiple abstracts from WCLC and ESMO 2022 and round table discussion with other Thoracic oncologists

 

●        Adjuvant Immunotherapy in NSCLC (Molecular Tumor Board) on 3/28/22

o         Discussion on the updates of adjuvant immunotherapy in NSCLC that included the IMpower010 with adjuvant Atezolizumab and chemotherapy and PEARLS/KEYNOTE-091 trial with adjuvant Pembrolizumab +/- chemotherapy. Future directions of both neoadjuvant and adjuvant trials for NSCLC

 

●        The ABCs of COVID-19 in Thoracic oncology: Alpha to Omicron. Lee, M. Halmos, B. (National COVID Lung Cancer Consortium. March 1st, 2022.

o         A presentation on the previous COVID-19 research conducted at Montefiore and a focus on the research on Omicron and the results of the study that examined Omicron variant impact on oncology patients

 

●        Montefiore Hematology Grand Rounds (June 4th 2021): DIC, Purpura Fulminans and ADAMTS13 deficiency, Oh My!

o         An overview of a rare case of purpura fulminans from Neisseria meningitidis bacteremia that led to TTP and the diagnostic challenges and treatment management that was needed to overcome it. The presentation also went into the novel strategies used and the varied outcomes afterwards and for future research needs.

 

●        Impact of visceral pleural invasion (VPI) and lymphovascular invasion (LVI) on stage I Non-small cell lung cancer (NSCLC) outcomes. Cohn E., Lee, M. Seetharamu, N. Virtual IASCLC 2021 World Lung Conference, September 8-14, 2021.

o         Retrospective study update from previous study examining stage I NSCLC patients with which included patients up to January 2020 with new results showing stage Ib with VPI and LVI with significantly higher recurrence than stage Ia patients (p=0.00001) and overall VPI and LVI positive patients had higher recurrence than those patients without but no differences in mortality. Larger studies are needed to further to evaluate VPI and LVI as predictive and prognostic biomarkers to determine adjuvant chemotherapy

 

●        “Examining Hospital-Related Outcomes for Hospice Eligible Elderly Patients with Solid Tumors, Does Hospice Enrollment Make a Difference?” Lee M, Lopez S. (Presented at the National American Society of Geriatrics Conference in Portland, 5/1-5/4/19, poster presentation and Hofstra Northwell Zucker Medical School Academic Day on 5/20/19)

o         Retrospective cohort study on metastatic solid tumor patients and whether they enrolled in hospice compared to those not enrolled in hospice (LACE >10, Karnofsky <50%) made a difference in hospital related outcomes (ICU admissions, mortality, DNR status, palliative unit admissions etc). Found significant differences in odds ratios of DNR, ICU admissions and palliative consults and no significant differences in mortality. Future studies needed on expanding hospital related outcomes to intubations, pressor support, hospital acquired infections with larger cohort studies.

 

●        “Safety and efficacy of Kcentra for the reversal of direct oral factor Xa inhibitor-associated bleeding and urgent/emergent surgery.” Ho Chris, Lee M (Presented at the New York State Council of Health-system Pharmacist Annual Assembly, 4/12/19, poster presentation)

o         This retrospective cohort study was to examine the effects of Kcentra given for oral FXa inhibitors (Apixaban, Rivaroxaban) in setting of a bleeding event (Gastrointestinal (GI), genitourinary (GU), intracranial (ICH) bleeding. Outcomes included repeat CT head scans showing improvement or unchanged status and <20% decrease in hemoglobin at 12 hours compared to baseline. Safety outcomes of thromboembolic events within 30 days of Kcentra included MIs, DVTs, Ischemic stroke, arterial thrombosis. Kcentra had 88% effective hemostasis in ICH and GI/GU 77% similar to other prior studies. Only 5% had either PE (2%), DVT (2%) or ischemic stroke (1%) by 30 days after Kcentra. Examine further thrombotic events past 30 days, rate of anticoagulant initiation and examine the optimal dosing of Kcentra to achieve hemostasis in various dosing of FXa inhibitors

 

●        “A Case Report of Creutzfeldt Jakob Disease in a Former Healthcare Worker: A Potentially Overlooked Risk Factor” Lee M, Gabbidon E (Presented at the National American College of Physicians Conference in Philadelphia, 4/11-13/19, poster presentation)

●        Schwartz Rounds on “Masquerading Autoimmune Encephalitis” at Long Island Jewish Medical Center (9/26/18)

●        “A Rare Initial Presentation of Lung Cancer Metastasis” Lee M, Sheth S, Ahmad S, Chang Q, Seetharamu N (Presented at the National American College of Physicians Conference, New Orleans, 4/19-21/18)

●        “Marchiafava-Bignami Disease-A Rare Complication of Alcoholism” Lee M, Otkins J, Geltman J, Yingqiu X. SHM (Presented at the Society of Hospital Medicine, Orlando, 4/8-4/11/18), Hofstra Northwell Zucker Medical School Academic Day (6/2018), NYACP Semi-Annual Conference at Westchester, NY (6/2018)

●        “Identifying potential health predictors in Health and Education Alternative for Teens (HEAT’s) Sexually Transmitted Infection screening program” Lee M, Birnbaum J, Rosenbaum J (Presented at the NYC Epidemiology Forum at NYU, 2/2017 and MPH Thesis 6/2017)

●        “Hybrid spheroid Assay potential use as an individualized treatment protocol” Lee M, Lange C. (2012-2017) (Journal Club Presentation)

o         Hybrid spheroid assays are microenvironments of tumor cells agglomerated into HeLa cells used for cancer stem cell growth models/measurements. Main objective was on automating the assays for clinical trials and optimize treatments based on cancer stem cell sensitivities to possible treatment agents and radiation survival curves. Measures the sensitivity of individual patient CSCs to proposed therapies, to be able to individualize patient treatments and speed anti-cancer agent development.

●        “Binding of Methylene Blue with Calf-Thymus DNA as a Test for a Microplate DNA Binding Assay” Lee M, Davenport L. (2009-2013, Brooklyn College Science Day, Chemistry)

●        “Determination if CUL-4A specifically mediates degradation of HOXA5 proteins” Lee M, Lee J (2009, Winner of US Army Award, NYCSEF 2009, Intel Project)

o         HOX genes are developmental genes in embryogenesis and hematopoiesis and have been shown to have altered expressions in numerous cancers such as breast, ovarian, NSCLC, colorectal tumors, AML. The aim of the project was to determine if CUL4A, a ubiquitin ligase that is also found to have an aberrant expression in multiple tumors, effects specifically HOXA5 proteins. HOXA5 have been shown to have decreased expression in breast cancer cells due to methylation silencing during early stages of tumorigenesis. Conclusion was that there was no relationship between CUL-4A and it does not seem to play a role.

●        Cyclic Ureides (Hydantoins) involving Taurine, GABA and Amantadine Structures (2008 Finalist in the New York Science and Engineering Fair and Junior Science and Humanities Symposium, Third Place Winner in Chemistry, and Winner of the Yale Science & Engineering Association Award for “Most Outstanding 11th Grade Exhibit”)

●        Curcumin Derivatives as Anti-Alzheimer Agents (2007, Semifinalist in the New York Science and Engineering Fair and Region 7 Science Fair)

 

Laboratory Experience

_________________________________________________________________________________________________

●        John Hopkins Sidney Kimmel Comprehensive Cancer Center, Pediatric Oncology with Dr. Robert J. Arceci, Dr. Joseph Moore, Dr. Qing-Song and Dr. Jason Farrar (Summer 2012)

o         NCI TARGET initiative in pediatric relapsed ALL genetics and to identify mutations and epigenetic alterations of relapsed patients

●        Brooklyn College with Dr. Lesley Davenport Biochemistry Department (2012)

●        SUNY Downstate with Dr. Christopher Lange Radiation Oncology Department (2009-2012)

●        Weill Cornell Graduate School of Medical Sciences Department of Pathology (2008-2009)

●        Institute of Basic Research (IBR) - Department of Neurochemistry (2007-2008)

●        College of Staten Island - Department of Biochemistry (2006-2007)

 

 

Skills and Advanced Specialized Courses

_________________________________________________________________________________________________

●        Statistical Computer Application of Biostatistics (MPH course), SPSS and R statistical programming 

●        Principle of Research Methodology (MPH course)

●        FDA-ASCO Workshop on Oncology Drug Development: Bench to Bedside (November 16, 2021)

 

Professional activities:

_________________________________________________________________________________________________

Membership:

●        ECOG committee (2022-current)

o         ECOG Thoracic committee member (Chairs: Julie Brahmer and Hossein Borghaei) 

o         ECOG Real-World data committee member (Chair: Charu Aggarwal)

●        American Society of Clinical Oncology (ASCO) (2017-current)

●        International Association for the Study of Lung Cancer (IASLC) (2020-current)

●        American Society of Hematology (ASH) (2020-current)

●        CLOT (Coalition of Leadership on Thrombosis) Council member (2018-2020)

●        American Society of Geriatric Society (AGS) (2017-2020)

●        Society of Hospital Medicine (SHM) (2017-2020)

●        American College of Physicians (ACP) (2013-2020)

●        American Medical Association (AMA) (2013-2020)

●        Medical Society of the State of New York (MSSNY) (2013-2020)

 

Public Health experience:

●        IMPACcT (Improving Patient Access, Care, and Cost through Training) clinic (2018-2020)

●        Brooklyn Free Clinic (BFC) and Downstate Community Health Fair Outreach (2015-2017)

●        NYCDOHMH (New York City Department of Health and Mental Hygiene) HRTP (Health Research Trainee Program), Intern at the Primary Care Access (2012-2013)

 

Global Health experience:

●        Global Health Elective in Uganda (Doctors for Global Health (2020)

●        Global Health Elective in Bangkok, Thailand at Siriraj Hospital (2017)

●        Global Medical Brigades Honduras (2011)

 

Advisory group/Consultantships:

  • Caris (Thoracic Working Group and Healthcare disparities Group)
  • FoundationOne
  • MJH Health consultants
  • PrecisCA

 

Honors and Awards

______________________________________________________________________________

●        IASLC WCLC Early Career Education Award (2023)

●        Texas Lung Cancer Conference Poster Finalist Award (2023)

●        Stacey Garil-Womack Scholarship Award for internship at John Hopkins Sidney Kimmel Comprehensive Cancer Center with Dr. Robert J. Arceci, Dr. Joseph Moore, Dr. Qing-Song and Dr. Jason Farrar (2013)

●        Chemistry Department Award, Kalberman Award (2013), Irving Feldman Memorial Award (2012)

●        Phi Beta Kappa Honor Society (Spring 2012 -2013)

●        Golden Key International Honor Society (2009-2013)

●        NYCSEF US Army Award in Biological Research (2009)

 

 

 

 

Date: 4/4/24

 

Signature:

A blue line on a white background Description automatically generated

Matthew Lee• (347) 837-5787